Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

August 14, 2012

Primary Completion Date

November 9, 2016

Study Completion Date

November 9, 2016

Conditions
Prostate Cancer
Interventions
DRUG

GTx-758 125 mg

One 125 mg tablet once a day

DRUG

GTx-758 250 mg

two 125 mg tablets once daily

Trial Locations (26)

12208

Urological Institute of NE New York, Albany

13210

AMP of NY, Syracuse

13421

AMP of NY, Oneida

19004

UCSEPA, Bala-Cynwyd

21204

Chesapeake Urology Research Assoc., Towson

23462

Urology of Virginia, Virginia Beach

28025

Carolina Clinical Trials, Concord

33145

AMPM Research, Miami

33180

So. Florida Medical Research, Aventura

33710

GTx Investigative Site, St. Petersburg

Pinellas Urology, St. Petersburg

34237

Coastal Medical Center, Sarasota

38119

West Clinic, Memphis

45212

The Urology Group, Cincinnati

46143

Urology of Indiana, Greenwood

47130

First Urology PSC, Jeffersonville

59808

Five Valleys Urology, Missoula

80045

Univ. of Colorado Cancer Center, Aurora

90073

VA of Greater Los Angeles, Los Angeles

90078

Tower Urology, Los Angeles

90505

Urology Specialists of So. California, Torrance

91505

Urology Associates Medical Group, Burbank

92123

Genesis Healthcare Partners, San Diego

92404

San Bernardino Urological Assoc., San Bernardino

98195

Seattle Cancer Care Alliance, Univ. of Washington, Seattle

06762

Connecticut Clinical Research Center, Middlebury

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GTx

INDUSTRY

NCT01615120 - Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer | Biotech Hunter | Biotech Hunter